2022
Polypharmacy and medical intensive care unit (MICU) admission and 10-year all-cause mortality risk among hospitalized patients with and without HIV
Gordon KS, Crothers K, Butt AA, Edelman EJ, Gibert C, Pisani MM, Rodriguez-Barradas M, Wyatt C, Justice AC, Akgün KM. Polypharmacy and medical intensive care unit (MICU) admission and 10-year all-cause mortality risk among hospitalized patients with and without HIV. PLOS ONE 2022, 17: e0276769. PMID: 36302039, PMCID: PMC9612570, DOI: 10.1371/journal.pone.0276769.Peer-Reviewed Original ResearchConceptsMedical intensive care unit admissionIntensive care unit admissionCare unit admissionMICU admissionSeverity of illnessHazard ratioHIV statusUnit admissionCause mortalityHospitalized patientsElectronic health record cohortLevel of polypharmacyRetrospective cohort studyCause mortality riskCohort studyHIV infectionCox regressionPolypharmacyMortality riskFiscal year 2009AdmissionPatientsMortalitySubstance useStrong association
2020
Polypharmacy and frailty among persons with HIV
Sung M, Gordon K, Edelman EJ, Akgün KM, Oursler KK, Justice AC. Polypharmacy and frailty among persons with HIV. AIDS Care 2020, 33: 1492-1499. PMID: 32880183, PMCID: PMC7925692, DOI: 10.1080/09540121.2020.1813872.Peer-Reviewed Original ResearchConceptsNon-ARV medicationsVeterans Aging Cohort StudyFrailty-related phenotypeLow physical activityAging Cohort StudyCross-sectional studyWarrants further studyUninfected participantsAntiretroviral therapyCohort studyRefill dataAdjusted analysisViral loadPolypharmacyPhysical activityGeneral populationMedicationsPLWHFrailtyStrong associationFurther studiesHIVPrimary predictorAssociationLarge proportionPolypharmacy in HIV: recent insights and future directions.
Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Current Opinion In HIV And AIDS 2020, 15: 126-133. PMID: 31833963, PMCID: PMC7543953, DOI: 10.1097/coh.0000000000000608.Commentaries, Editorials and LettersConceptsSeverity of illnessInappropriate medicationsDrug interactionsActual adverse eventsSubstance useTotal drug burdenMechanism of injuryElectronic health recordsNonantiretroviral medicationsUpdate findingsMore medicationsAdverse eventsDrug burdenClinical managementPolypharmacyDirect biomarkerMedicationsModifiable mechanismsPWHSicker individualsHealth recordsStrong associationHIVInjuryIllness
2018
Using DNA methylation to validate an electronic medical record phenotype for smoking
McGinnis KA, Justice AC, Tate JP, Kranzler HR, Tindle HA, Becker WC, Concato J, Gelernter J, Li B, Zhang X, Zhao H, Crothers K, Xu K, Group F. Using DNA methylation to validate an electronic medical record phenotype for smoking. Addiction Biology 2018, 24: 1056-1065. PMID: 30284751, PMCID: PMC6541538, DOI: 10.1111/adb.12670.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyAging Cohort StudyStrong associationDNA methylation sitesSmoking metricsCohort studyCurrent smokingSmoking statusSpearman correlation coefficientBiomarker cohortBlood samplesSmoking behaviorCriterion standardLogistic regressionSmokingSmoking phenotypesCurve analysisGroup assignmentText notesAssociationDescriptive statisticsPhenotypeCorrelation coefficientGenetic discoveriesPercent